Clinical analysis and evaluation of docetaxel Health Articles | June 7 Dalvin Tomlinson Black Jersey , 2012
Docetaxel is a new anticancer drug belonging to taxane compounds. It is one kind of powder with white or nearly white color. Its action mechanism is to enhance tubulin polymerization and inhibit microtubule depolymerization, resulting in the formation of stable non- functional microtubules.


Then it undermines the mitosis of tumor cells. In recent years, docetaxel has been widely used in the clinical treatment of various tumors. Pharmaceutical raw materials suppliers are involved in production of docetaxel.


Docetaxel is a new generation of semi-synthetic taxane anticancer drugs. Results from clinical trials show that docetaxel-based adjuvant chemotherapy can improve the long-term survival and reduce the risk of recurrence of early breast cancer. Metastasis and recurrence in patients with advanced breast cancer in recent years is on the rise, and how to prolong survival and improve quality of life is a clinical need to be resolved. Comprehensive treatment with chemotherapy is still the best choice, especially the advent of the taxane Evan Engram Black Jersey , so that the efficacy of chemotherapy of breast cancer has been markedly improved. One of the most commonly used standard programs: a ring of doxorubicin CTX more than one docetaxel used as a positive axillary lymph nodes and no distant metastatic disease in early breast cancer adjuvant therapy.


Advanced non-small cell lung cancer to chemotherapy and symptomatic treatment, clinical studies show docetaxel has a good effect in drug-resistant lung cancer. Compared with traditional drug cisplatin in NSCLC, docetaxel and cisplatin mechanism of action is different from and no cross-resistance with cisplatin resistance is also effective, the effective rate of 16% to 22%. In the toxicity of cisplatin oto-renal toxicity, docetaxel-oto-renal toxicity. Currently Saquon Barkley Black Jersey , the targeted therapy as a new means in the treatment of NSCLC. A clear advantage, but is not recommended for clinical targeted therapy as first-line treatment, while more than docetaxel only can be used as first-and second-line treatment drugs. The research data show that docetaxel single-agent first-line treatment of advanced non-small cell lung cancer to ensure the efficacy at the same time, better tolerated by patients, so more than docetaxel single-agent first-line treatment of non-small cell lung cancer has a good application prospects.


Docetaxel in gastric cancer has a high activity Lawrence Taylor Black Jersey , first, the objective response rate of second-line monotherapy for gastric cancer in more than 20%. In particular, despite the international, multi-center trial registered patients with nearly l00% of the tumor has already spread outside the stomach in patients with advanced, but to accept the combination of docetaxel and cisplatin-fluorouracil in the treatment of those 1-year survival rate was significantly increased. The trial has reputation as milestone significance and for the past 20 years the most important